ArticleMolecular medicine reports2019
Protective effect of dihydromyricetin revents fatty liver through nuclear factor‑κB/p53/B‑cell lymphoma 2‑associated X protein signaling pathways in a rat model.
Article in Molecular medicine reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 1 synthesis or guideline pooled it, 17 citations in OpenAlex.
- Pharmacological effects of dihydromyricetin in preclinical models of NAFLD: a systematic review and meta-analysis stratified by dose and duration.Frontiers in pharmacology · 2026Pooled it
- Unrevealing the Role of Flavonoids in Mitigation of Non-Alcoholic Fatty Liver Disease.Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents · 2026Review
- Study on the Protective Mechanism of Dihydromyricetin Against Aflatoxin BCurrent issues in molecular biology · 2025Article
- Preclinical research of dihydromyricetin for fibrotic diseases.Frontiers in pharmacology · 2025Review
- Research advances in traditional Chinese medicine formulae and active components targeting lipid metabolism for hepatocellular carcinoma therapy.Frontiers in pharmacology · 2025Review
- Dihydromyricetin alleviates inflammatory bowel disease associated intestinal fibrosis by inducing autophagy through the PI3K/AKT/mTOR signaling pathway.Naunyn-Schmiedeberg's archives of pharmacology · 2024Article
- Multiple molecular and cellular mechanisms of the antitumour effect of dihydromyricetin (Review).Biomedical reports · 2024Review
- Dihydromyricetin supplementation improves ethanol-induced lipid accumulation and inflammation.Frontiers in nutrition · 2023Article
- Present Status, Challenges, and Prospects of Dihydromyricetin in the Battle against Cancer.Cancers · 2022Review
- Dihydromyricetin Acts as a Potential Redox Balance Mediator in Cancer Chemoprevention.Mediators of inflammation · 2021Review
- Dihydromyricetin Alleviates High Glucose-Induced Oxidative Stress and Apoptosis in Human Retinal Pigment Epithelial Cells by Downregulating miR-34a Expression.Diabetes, metabolic syndrome and obesity : targets and therapy · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dihydromyricetin is the major flavonoid in vine tea, whose pharmacological action has attracted increasing attention in recent years. The triglyceride, albumin (ALB), alanine aminotransferase, aspartate aminotransferase, malondialdehyde, superoxide dismutase, glutathione (GSH), GSH peroxidase, tumor necrosis factor‑α, interleukin (IL)‑1β, IL‑6 and IL‑18 expression levels were measured using enzyme‑linked immunosorbent assay kits. The protein levels of ALB and collagen I, PPARα, NF‑κB, p53 and Bax were used to measure using western blotting. The results revealed that dihydromyricetin prevented the development of fatty liver, and inhibited oxidative stress, inflammation and apoptosis in a fatty liver rat model. In addition, treatment with dihydromyricetin inhibited the levels of ALB and collagen I, while it induced peroxisome proliferator‑activated receptor α protein expression. Dihydromyricetin also suppressed the protein expression levels of nuclear factor (NF)‑κB, p53 and B‑cell lymphoma 2‑associated X protein (Bax) in the rat model. Collectively, it is concluded that dihydromyricetin exerted a protective effect on fatty liver through NF‑κB/p53/Bax signaling pathways in a rat model.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.